Drug intelligence / Profile preview

ARGX-118

Development stage: Preclinical
Lead developer: argenx
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

ARGX-118 is a monoclonal antibody designed to inhibit Galectin-10, a protein that forms Charcot-Leyden crystals involved in airway inflammation and asthma. The drug aims to dissolve these crystals, thereby modulating immune responses and reducing mucus plugging in the respiratory tract. ARGX-118 represents a novel, first-in-class approach under development by argenx in collaboration with VIB for the treatment of disorders such as asthma and chronic airway inflammation. As of the most recent updates, ARGX-118 remains in preclinical development, and no clinical trial approvals or reported adverse events are available[1][3][5][6].

Brand names: ARGX-118ARGX118ARGX 118
Other names: ARGX 118ARGX118ARGX-118

Targets

LGALS10 (Galectin-10)

Beyond the preview

Go deeper on ARGX-118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARGX-118.

Explore the full profile